Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home / Old top news stories / UNC scientists identify possible KRAS downstream target for pancreatic cancer therapy

UNC scientists identify possible KRAS downstream target for pancreatic cancer therapy

While the mutated KRAS oncogene is associated with many cancers, it has not yet been successfully targeted by a therapeutic agent. Scientists are trying to find another way to target the gene by blocking signals from another protein downstream.

A University of North Carolina School of Medicine team offers first evidence of the role of a protein called GSK-3 alpha in promoting oncogenic KRAS function. When the scientists inhibited GSK-3 in a model of pancreatic tumors, the team got a strong anti-tumor response, thus offering a potential therapeutic option.  Their findings are published in the June issue of the journal Cancer Discovery.

Albert Baldwin, William Rand Kenan Professor Biology, study senior author, and associate director of UNC Lineberger Comprehensive Cancer Center, says, “GSK-3 promotes activity of a protein called NF-kappa B. Our lab has been studying NF-kappa B for a number of years and has published that this protein is important in KRAS signaling.  But how KRAS activates NF-kappa B has not been well understood.  We have found a link.”

GKS-3 has alpha and beta forms. The beta form has been studied and is considered to be a tumor suppressor. GSK-3 alpha was considered to be redundant to GSK-3 beta. The research team studied GSK-3 alpha in mice with human pancreatic tumors and found through their experiments that its function is different from GSK-3 beta.

“Our data suggest that GSK-alpha is really an onco-protein and that KRAS utilizes GSK-alpha to activate both NF-kappa B pathways, called canonical and noncanonical. This finding is important because GSK-3 alpha sits on top of the two pathways and inhibits them both, thus making it a viable therapeutic target. We are conducting further pharmacologic studies,” said Baldwin.

UNC study co-authors are Deepali Bang, MS; Willie Wilson, PhD, now at the National Cancer Institute; Meagan Ryan, BS, and Jen Jen Yeh, MD.  

Support for the research was funded by NIH CA7508, NIH CA 73756, NIH CA140424, the Waxman Cancer Research Foundation, and the UNC Biological and Biomedical Sciences Program. 

Date: May 28, 2013

Filed under: